Korean Diabetes Association (KDA), Korea’s first healthcare-focused English online paper Korea Biomedical Review (KBR), and KBR’s sister paper The Korean Doctors’ Weekly agreed to work together to promote Korean medicine internationally.
KDA, KBR, and The Korean Doctors’ Weekly signed a memorandum of understanding for global promotion of Korean medicine at KDA’s office in Seoul, on Wednesday.
The two sides agreed to publish news articles on the latest information and research papers on diabetes in Korea, promote KDA’s academic conferences at home and abroad, and publicize issues about local diabetes policy, treatment guidelines, and diabetes-related healthcare.
They also agreed to support KDA to become a leading group to set global standards in diabetes research and treatment.
“KDA was established in 1968. Marking the 50th anniversary last year, we reflected on what KDA should do next. Working with KBR is in line with what KDA has to do in the future,” said KDA Board of Directors Chairman Park Kyong-soo. “With the MOU with KBR and The Korean Doctors’ Weekly, I hope KDA could enhance its competitiveness.”
Park noted that foreign researchers are increasingly writing contributions for Diabetes & Metabolism Journal (DMJ), the KDA’s Science Citation Index Expanded (SCIE) journal published six times a year. He hoped that KBR could introduce more excellent papers published in DMJ to international readers.
Yang Kyung-cheol, CEO of KBR and The Korea Doctors’ Weekly, said, “It is an honor for KBR, the nation’s only English paper to cover healthcare issues exclusively, to sign an MOU with KDA, one of the nation’s representative medical societies.”
According to Yang, many prestigious healthcare news media outlets are covering Korea’s healthcare news through KBR articles. He said KBR would play a bridging role in promoting KDA’s quality research papers globally.
KBR Executive Editor Choi Sung-jin also said although many pledges “globalization” in words, it is rare to see an organization or a company in Korea that took action to go global. “KBR will thoroughly cover KDA’s achievements and help it become a global leader in diabetes treatment,” he added.